Dr Mia Biondi – Perinatal hepatitis C screening, care and treatment: Preconception to paediatrics
Keywords
Summary
140 words
Critical Evaluation
Value of the Information & Strength of the Argument
The presentation provides valuable insights into the current state of perinatal HCV care, supported by recent data and guidelines. The argumentation is solid, drawing on epidemiological studies, systematic reviews, and clinical experience. The speaker effectively argues for universal screening and case-by-case treatment in pregnancy, backed by evidence of safety and efficacy. She also highlights critical gaps in care, such as low postpartum treatment rates and inadequate pediatric screening, making a strong case for improved care pathways.
Scientific Rigor, Source Quality, Title Accuracy
The presentation demonstrates scientific rigor, referencing key studies and guidelines from Canada, the US, and international bodies. The speaker clearly distinguishes between guideline-driven recommendations and her own clinical opinions, and discloses off-label medication use. The title accurately reflects the content, covering the full spectrum of perinatal HCV care. The speaker also acknowledges limitations, such as outdated Canadian data and the need for more research in certain areas.
158 words
Title / Content Match
The title accurately reflects the content, covering the full spectrum from preconception to pediatric care.
Quality & Reliability
8/10
Presentation by a recognized expert in hepatitis C care, based on published studies, Canadian guidelines, and clinical experience. Data sources are credible, but some recommendations are based on expert opinion and off-label use.
Key Moments
Markers derived by PSI from the transcript: the creator did not define chapters.
- Introduction and acknowledgments
- Overview of hepatitis C epidemiology in women and pregnant individuals
- Discussion of stigma and its impact on healthcare seeking behavior
- Quality improvement project in a residential drug treatment facility
- Data from Canadian administrative database on women with HCV
- Qualitative study on Indigenous communities and connection/disconnection/reconnection
- Shift to perinatal HCV focus, language and definitions
- Updates in perinatal HCV screening and treatment
- Canadian provincial prevalence data and universal screening implementation
- Evidence for treatment in pregnancy and pediatric screening gaps
Cited Sources
- Kirby Institute event page — Event description and speaker biography
Concurring Sources
- AASLD/IDSA HCV Guidance — Recommendations for universal screening and treatment in pregnancy
- EASL Clinical Practice Guidelines — European guidelines supporting universal screening and case-by-case treatment
Dissenting Sources
- Canadian guidelines (2018) — Older Canadian guidelines recommended against treatment in pregnancy, which the speaker argues is outdated.
Contribution & Novelties
The presentation provides a comprehensive and up-to-date synthesis of perinatal HCV care, highlighting recent shifts in screening and treatment recommendations. It emphasizes the importance of a gender lens and the need for tailored approaches for women and pregnant individuals. The speaker shares Canadian data and clinical insights that may not be widely known, contributing to the field.
Pour aller plus loin :
- WHO guidelines on hepatitis C — Official guidelines for HCV care.
- AASLD/IDSA HCV Guidance — Recommendations for testing, managing, and treating hepatitis C.
- CDC recommendations for HCV screening — US screening guidelines.
94 words
Radar Profile
The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating a presentation that is comprehensive and evidence-based but accessible to a broader audience.